Lyra Therapeutics, Inc. LYRA
0.20
0.17
566.67%
as of 25 Sep
- Market cap
- $870.0K
- P/E
- 0.0×
Follow LYRA
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.02 | 19.24 | 15.70 | 7.01 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.79) | (1.57) | (1.83) | (0.94) | |
P/B ratio |
0.00 | 0.00 | 7.45 | 2.15 | |
Price to Tangible BV |
0.00 | 0.00 | 7.45 | 2.15 | |
EV/Sales |
(27.91) | (17.52) | (22.98) | (19.77) | |
EV/EBITDA |
0.36 | 0.30 | 0.42 | 0.28 | |
EV/Operating CF |
0.39 | 0.31 | 0.41 | 0.42 | |
EV/FCF |
0.38 | 0.31 | 0.41 | 0.40 | |
Quick Ratio |
1.67 | 2.33 | 2.67 | 2.77 | |
Current Ratio |
1.71 | 2.43 | 2.78 | 2.96 | |
Net Debt/EBITDA |
2.26 | 3.60 | 3.42 | 3.64 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.87 | 1.23 | 0.89 | 1.03 | |
Capex/Depreciation |
(0.96) | 0.00 | (0.02) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
62,542.86% | 16,188.00% | 2,792.35% | 2,664.48% | |
Selling, General and Administrative Expense of Revenue |
36,285.71% | 8,944.00% | 1,913.11% | 1,783.06% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8,028.57% | 136.00% | 499.45% | 450.82% | |
Graham Net Nets |
(6.39) | (2.17) | (1.65) | (2.23) | |
Graham Number |
54.53 | 35.89 | 0.00 | 0.00 | |
Earnings Yield |
(621.75%) | (358.19%) | (323.77%) | (957.28%) | |
Free Cash Flow Yield |
(604.17%) | (295.71%) | (357.39%) | (706.64%) | |
Revenue per Share |
0.00 | 0.01 | 0.14 | 0.14 | |
Operating CF per Share |
(3.91) | (4.16) | (4.89) | (6.72) | |
Capex per Share |
(0.06) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.97) | (4.16) | (4.89) | (6.72) | |
Cash per Share |
10.23 | 12.47 | 22.08 | 24.13 | |
Shareholders Equity per Share |
(6.90) | (2.45) | 1.20 | 2.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(6.90) | (2.45) | 1.20 | 2.94 | |
Free Cash Flow |
(6.16) | (7.36) | (6.59) | (8.84) | |
Working Capital |
6.75 | 13.54 | 19.90 | 22.44 | |
Capital Expenditures |
(0.10) | 0.00 | 0.00 | — | |
Net Current Asset Value |
(30.55) | (25.02) | (19.89) | (18.54) | |
EV/EBIT |
0.36 | 0.30 | 0.43 | 0.29 | |
Capex to Sales |
13.71 | 0.00 | 0.01 | 0.00 | |
Net Profit Margin |
(99,300.00%) | (23,936.00%) | (4,063.93%) | (4,670.49%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.92 | 1.46 | 2.83 | 1.78 | |
Average Assets |
51.23 | 61.23 | 73.58 | 98.92 | |
Average Common Equity |
0.44 | 8.15 | 16.30 | 40.69 |
Columns are period end dates